CAC
CKPT

Cowen and Company’s Checkpoint Therapeutics CKPT Stock Holding History

Cowen and Company’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-220,000
Closed -$495K – 592
2023
Q1 		$495K Buy
+220,000
New +$1.1M 0.06% 119

Other funds holding CKPT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Cowen and Company's CKPT Position: Q2 2023 in Review

Cowen and Company sold out of Checkpoint Therapeutics (CKPT) in Q2 2023, closing a stake of 220,000 shares — an estimated $495K sold.

Cowen and Company first reported a position in CKPT in Q1 2023 and held it in 1 quarter. The position peaked at $495K in Q1 2023. 34 funds tracked by Wall St. Rank hold CKPT as of Q2 2023.

  • Cowen and Company reported no remaining Checkpoint Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cowen and Company sold 220,000 Checkpoint Therapeutics shares in Q2 2023, an estimated $495K.
  • Cowen and Company first reported a position in Checkpoint Therapeutics in Q1 2023 and held it in 1 quarter.
  • Cowen and Company's Checkpoint Therapeutics position peaked at $495K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2023.

Based on Cowen and Company's 13F filing for Q2 2023, filed 7 Aug 2023.